Stryker Corp Stock Price, News & Analysis

Stryker (NYSE:SYK) has announced a quarterly dividend increase of 5.0%, declaring a payment of $0.84 per share. The dividend will be payable on January 31, 2025, to shareholders of record as of December 31, 2024. The company's Chair and CEO Kevin Lobo attributed this increase to Stryker's strong financial performance, aligning with their capital allocation priorities.

Stryker (NYSE: SYK) has introduced the Oculan Lighting Platform, an advanced surgical lighting solution designed to enhance operating room visualization. The platform features proprietary Fly Eye technology for even light distribution, consistent illumination, and specialized modes like Auto lux and Microspot for uniform brightness in deep cavities. The system includes SHD Mode for improved contrast and tissue differentiation, along with heat minimization features for surgeon comfort during lengthy procedures. The platform is compatible with existing Stryker surgical lights and offers multiple control points for streamlined workflow.

Stryker (NYSE:SYK) has launched the next generation of SurgiCount+, now integrated with Triton technology, to address retained surgical sponges and blood loss assessment challenges. The system features AI technology that differentiates blood from other fluids and includes a Bluetooth scale for weighing blood-soaked items. The solution helps prevent retained surgical items, which occur in 88% of cases with false correct counts, and assists in managing maternal hemorrhage cases, of which 70% are preventable. The integrated platform streamlines workflow efficiency, reduces manual data entry errors, and provides real-time EMR integration.

Stryker (SYK) reported strong Q3 2024 results with net sales increasing 11.9% to $5.5 billion. The company achieved an organic net sales growth of 11.5%, driven by 10.3% from increased unit volume and 1.2% from higher prices. The reported operating income margin reached 19.7%, while adjusted operating income margin improved by 130 basis points to 24.7%. Reported EPS grew 20.0% to $2.16, and adjusted EPS increased 16.7% to $2.87. Based on strong performance, Stryker raised its full-year 2024 organic net sales growth guidance to 9.5-10.0% and adjusted EPS guidance to $12.00-$12.10.

Stryker (NYSE: SYK) has completed the acquisition of NICO , a privately held company specializing in minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition strengthens Stryker's position in neurotechnology, particularly in tumor and stroke care. ICH, the deadliest form of stroke, affects over 3.4 million people annually worldwide, with a 30-day mortality rate of 40-50%.

NICO's BrainPath® and Myriad® products offer improved functional outcomes for ICH treatment compared to standard medical management. Andy Pierce, group president of MedSurg and Neurotechnology at Stryker, stated that this strategic addition will enable the company to deliver differentiated, minimally invasive approaches to drive meaningful outcomes and improve patients' lives globally.

Stryker (NYSE: SYK) has completed the acquisition of care.ai, a privately held company specializing in AI-assisted virtual care workflows, smart room technology, and ambient intelligence solutions. This acquisition is expected to strengthen Stryker's growing healthcare IT offering and wirelessly connected medical device portfolio. Andy Pierce, Group President of MedSurg and Neurotechnology at Stryker, expressed enthusiasm about accelerating the company's digital vision to provide customers with real-time, smart, and connected decision-making tools that can enhance the lives of caregivers and their patients. The acquisition aligns with Stryker's strategy to expand its technological capabilities in the healthcare sector.

Politan Capital Management, an 8.9% shareholder of Masimo (NASDAQ: MASI), has issued an open letter to shareholders ahead of the company's 2024 Annual Meeting on September 19. The letter highlights the need for further change in Masimo's boardroom and refutes the company's defensive rhetoric. Politan urges shareholders to vote for its independent nominees, Darlene Solomon and William Jellison, on the WHITE card.

Key points from the letter include:

• Criticism of Masimo's board for lack of oversight and transparency
• Allegations of collusion between Masimo's CEO and RTW to manipulate voting
• Refutation of Masimo's claims about potential business disruption
• Defense against Masimo's accusations towards Politan
• Emphasis on the urgent need for change in Masimo's governance

Politan argues that without a majority of independent directors, Masimo's pattern of poor governance and shareholder value destruction will continue.

Eko Health, a leader in AI-powered early detection of heart and lung diseases, has appointed Brent D. Lang to its Board of Directors. Lang, former Chairman and CEO of Vocera Communications, brings over 30 years of healthcare and technology experience. He led Vocera through rapid growth, a successful IPO, and its $3 billion acquisition by Stryker (NYSE: SYK).

This appointment follows Eko's recent achievements, including surpassing 500,000 healthcare providers on its platform, completing a $41 million Series D funding round, and receiving FDA clearance for an AI algorithm aiding heart failure detection during routine exams. Lang's strategic vision is expected to guide Eko's continued innovation and expansion in early disease detection technology.

Stryker (NYSE:SYK) has expanded its Foot & Ankle portfolio with two new products: the Osteotomy Truss System™ (OTS) and Ankle Truss System™ (ATS), acquired from 4WEB Medical. These innovations will be showcased at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Vancouver from Sept. 11-14, 2024.

The ATS, featuring Arthrosphere® and Arthrocube™ implants, is designed for tibiotalocalcaneal fusions, offering structural support and promoting fusion. The OTS provides a comprehensive solution for osteotomy needs. Stryker will also highlight the Artelon Flexband and celebrate the 10th anniversary of the Infinity Total Ankle System, which boasts a 95.9% survivorship rate at seven years.